BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Torrisi SE, Kahn N, Vancheri C, Kreuter M. Evolution and treatment of idiopathic pulmonary fibrosis. Presse Med 2020;49:104025. [PMID: 32437841 DOI: 10.1016/j.lpm.2020.104025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Torres-soria AK, Romero Y, Balderas-martínez YI, Velázquez-cruz R, Torres-espíndola LM, Camarena A, Flores-soto E, Solís-chagoyán H, Ruiz V, Carlos-reyes Á, Salinas-lara C, Luis-garcía ER, Chávez J, Castillejos-lópez M, Aquino-gálvez A. Functional Repercussions of Hypoxia-Inducible Factor-2α in Idiopathic Pulmonary Fibrosis. Cells 2022;11:2938. [DOI: 10.3390/cells11192938] [Reference Citation Analysis]
2 Egea-Zorrilla A, Vera L, Saez B, Pardo-Saganta A. Promises and Challenges of Cell-Based Therapies to Promote Lung Regeneration in Idiopathic Pulmonary Fibrosis. Cells 2022;11:2595. [PMID: 36010671 DOI: 10.3390/cells11162595] [Reference Citation Analysis]
3 Li J, Wang Y, Wang R, Wu MY, Shan J, Zhang YC, Xu HM. Study on the molecular mechanisms of tetrandrine against pulmonary fibrosis based on network pharmacology, molecular docking and experimental verification. Heliyon 2022;8:e10201. [PMID: 36046534 DOI: 10.1016/j.heliyon.2022.e10201] [Reference Citation Analysis]
4 Zang C, Zheng Y, Wang Y, Li L. The effects and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis: a meta-analysis and systematic review. Eur J Med Res 2021;26:129. [PMID: 34717762 DOI: 10.1186/s40001-021-00601-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk factors, and management. BMJ 2021;374:n1648. [PMID: 34312178 DOI: 10.1136/bmj.n1648] [Cited by in Crossref: 3] [Cited by in F6Publishing: 170] [Article Influence: 3.0] [Reference Citation Analysis]
6 Bos S, De Sadeleer LJ, Vanstapel A, Beeckmans H, Sacreas A, Yserbyt J, Wuyts WA, Vos R. Antifibrotic drugs in lung transplantation and chronic lung allograft dysfunction: a review. Eur Respir Rev 2021;30:210050. [PMID: 34415849 DOI: 10.1183/16000617.0050-2021] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Nwafor EO, Lu P, Liu Y, Peng H, Qin H, Zhang K, Ma Z, Xing B, Zhang Y, Li J, Liu Z. Active Components from Traditional Herbal Medicine for the Potential Therapeutics of Idiopathic Pulmonary Fibrosis: A Systemic Review. Am J Chin Med 2021;49:1093-114. [PMID: 34107859 DOI: 10.1142/S0192415X2150052X] [Cited by in F6Publishing: 1] [Reference Citation Analysis]